• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Leukemia Drug Pipeline Update 2015 Product Image

Leukemia Drug Pipeline Update 2015

  • ID: 1197060
  • January 2015
  • Region: Global
  • Bioseeker

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented.

There are today 318 companies plus partners developing 416 leukemia drugs in 668 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 157 drugs. Leukemia Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 297 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 283 out of the 288 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 66 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development READ MORE >

Note: Product cover images may vary from those shown

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Amgen Inc. Quest Diagnostics, Inc. Roche Diagnostics Ltd. Clariant International Ltd. IGen Biotech SL Abbott Laboratories Ltd.